Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...